Copyright
©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6329-6340
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6329
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6329
Table 1 American Diabetes Association Criteria for diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance
Terminology | ||
FPG (mg/dL) | < 100 | Normal |
100-125 | IFG | |
> 126 | Diabetes mellitus | |
2-h glucose after 75 g oral glucose load | < 140 | Normal |
140-199 | IGT | |
> 200 | Diabetes mellitus |
Table 2 Newcastle-Ottawa scoring system for cohort studies
Study | Selection score | Comparability score | Outcome score | Total score |
Saliba et al[1] | 4 | 2 | 3 | 9 |
Parolin et al[14] | 3 | 1 | 3 | 7 |
Baid et al[10] | 3 | 2 | 3 | 8 |
Schmilovitz et al[21] | 3 | 1 | 3 | 7 |
Moon et al[6] | 4 | 1 | 2 | 7 |
Kishi et al[22] | 4 | 2 | 3 | 9 |
Khalili et al[13] | 3 | 2 | 3 | 7 |
Yoshida et al[15] | 3 | 2 | 3 | 8 |
Gelley et al[23] | 3 | 2 | 3 | 8 |
Dehghan et al[17] | 4 | 2 | 2 | 8 |
Harada et al[24] | 3 | 2 | 2 | 7 |
Anderson et al[25] | 3 | 1 | 3 | 7 |
Ling et al[26] | 3 | 2 | 2 | 7 |
Zhao et al[27] | 3 | 2 | 1 | 6 |
Sánchez-Pérez et al[28] | 3 | 2 | 3 | 7 |
Mirabella et al[5] | 3 | 2 | 3 | 8 |
Driscoll et al[29] | 3 | 1 | 3 | 7 |
Honda et al[3] | 3 | 2 | 3 | 8 |
Carey et al[2] | 4 | 1 | 3 | 8 |
Table 3 Baseline characteristics of the included studies
Ref. | Year | Country | Total number | NODM | Follow-up | Reference number |
Saliba et al[1] | 2007 | France | 211 | 48 | 6-24 mo | 1 |
Parolin et al[14] | 2004 | Brazil | 82 | 15 | ≥ 1 yr | 14 |
Baid et al[10] | 2001 | United States | 136 | 52 | > 6 mo | 10 |
Schmilovitz et al[21] | 2003 | Israel | 91 | 27 | > 6 mo | 21 |
Moon et al[6] | 2006 | United States | 619 | 392 | 6-122 mo | 6 |
Kishi et al[22] | 2006 | Japan | 205 | 71 | > 6 mo | 22 |
Khalili et al[13] | 2004 | United States | 555 | 209 | 1.6-6.8 yr | 13 |
Yoshida et al[15] | 2013 | Canada | 280 | 89 | > 6 mo | 15 |
Gelley et al[23] | 2011 | Hungary | 206 | 63 | > 6 mo | 23 |
Dehghan et al[17] | 2008 | Iran | 170 | 44 | 6-156 > 6 mo | 17 |
Harada et al[24] | 2013 | Japan | 331 | 128 | 3.8-11.2 yr | 24 |
Anderson et al[25] | 2009 | United States | 45 | 11 | 6 mo | 25 |
Ling et al[26] | 2013 | China | 125 | 25 | 6-61 mo | 26 |
Zhao et al[27] | 2009 | China | 66 | 11 | 3-38 mo | 27 |
Sánchez-Pérez et al[28] | 2008 | Spain | 127 | 13 | > 6 mo | 28 |
Mirabella et al[5] | 2005 | India | 830 | 90 | > 10 mo | 5 |
Driscoll et al[29] | 2006 | United States | 115 | 36 | 12 mo | 29 |
Honda et al[3] | 2013 | Japan | 161 | 22 | > 3 mo | 3 |
Carey et al[2] | 2012 | United States | 225 | 39 | ≥ 1 yr | 2 |
Table 4 Baseline characteristics of the included studies
Ref. | Study year | Study design | Risk factors |
Saliba et al[1] | 2003.10-2004.6 | Retrospective | BMI, HCV, IFG, immunosuppression |
Parolin et al[14] | 2004.1-2004.6 | Retrospective | Gender, BMI, HCV, a family history of diabetes, alcohol |
Baid et al[10] | 1991.1-1998.10 | Retrospective | HCV |
Schmilovitz et al[21] | 1992-2002 | Retrospective | Gender, HCV, alcohol, immunosuppression, HBV |
Moon et al[6] | 1996.1-2004.10 | Retrospective | Gender, HCV |
Kishi et al[22] | 1996.1-2005.1 | Retrospective | HCV |
Khalili et al[13] | 1990-1994 | Retrospective | HCV |
Yoshida et al[15] | 1996.1-2006.10 | Retrospective | Immunosuppression |
Gelley et al[23] | 1995-2009 | Retrospective | HCV |
Dehghan et al[17] | 1994-2006 | Retrospective | Gender, HCV, BMI, immunosuppression, HBV |
Harada et al[24] | 1996.1-2011.1 | Retrospective | Gender, HCV, alcohol, HBV |
Anderson et al[25] | 2004.1-2005.10 | Retrospective | Gender, HCV, BMI, a family history of diabetes, alcohol, HBV |
Ling et al[26] | 2006.11-2009.7 | Retrospective | Gender, BMI, HBV |
Zhao et al[27] | 2001-2008.3 | Retrospective | Gender, IFG, a family history of diabetes, immunosuppression, HBV |
Sánchez-Pérez et al[28] | 1997.3-2001.10 | Retrospective | Immunosuppression |
Mirabella et al[5] | NR | Retrospective | HCV |
Driscoll et al[29] | 1998.1-2001.8 | Retrospective | CMV, gender, BMI, HCV, a family history of diabetes, immunosuppression |
Honda et al[3] | 1998.12-2011.10 | Retrospective | CMV, gender, HCV, BMI, a family history of diabetes |
Carey et al[2] | 1999.6-2008.2 | Retrospective | Gender, BMI, HCV, IFG, a family history of diabetes, alcohol, immunosuppression |
Table 5 Subgroup analysis
Risk factor | Subgroup | Studies, n | Effect estimate (95%CI) | P value | Heterogeneity |
HCV | United States | 5 | 2.29 (1.19-4.41) | < 0.01 | P = 0.004, I2 = 74% |
Other | 9 | 2.96 (2.11-4.15) | < 0.01 | P = 0.06, I2 = 46% | |
Overall | 14 | 2.68 (1.92-3.72) | < 0.01 | P = 0.004, I2 = 65% | |
HBV | Published before 2010 | 4 | 1.61 (0.94-2.78) | 0.08 | P = 0.23, I2 = 30% |
Published after 2010 | 2 | 0.59 (0.35-1.00) | 0.05 | P = 0.61, I2 = 0% | |
Overall | 6 | 1.04 (0.54-2.00) | 0.9 | P = 0.04, I2 = 57% |
- Citation: Li DW, Lu TF, Hua XW, Dai HJ, Cui XL, Zhang JJ, Xia Q. Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis. World J Gastroenterol 2015; 21(20): 6329-6340
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6329.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6329